NCT02421861

Brief Summary

The aims of this study are to (1) test the benefits of a non-pharmacologic anxiety management approach with patients who are critically ill and/or traumatically injured during intensive care hospitalization and (2) test whether this approach reduces anxiety and improves engagement in rehabilitation therapies, shortens duration of hospitalization, and improves psychological and quality of life outcomes.

Trial Health

10
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for phase_2 anxiety

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2015

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

April 10, 2015

Completed
11 days until next milestone

First Posted

Study publicly available on registry

April 21, 2015

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2016

Completed
Last Updated

November 1, 2016

Status Verified

October 1, 2016

Enrollment Period

10 months

First QC Date

April 10, 2015

Last Update Submit

October 28, 2016

Conditions

Keywords

anxietyintensive care unitcritical care

Outcome Measures

Primary Outcomes (1)

  • Anxiety (Visual Analog Scale for Anxiety (VAS-A)

    Anxiety at discharge and change in anxiety from baseline to discharge as measured by the Visual Analog Scale for Anxiety (VAS-A)

    Participants will be followed for the duration of hospitalization, an expected average of 13 days and not more than 45 days

Secondary Outcomes (5)

  • Engagement in rehabilitation therapies (As measured by a 2-item engagement questionnaire)

    As measured by a 2-item engagement questionnaire (developed specifically for this study) at the time of hospital discharge (i.e., based on an expected average duration of hospitalization of 13 days and not more than 45 days)

  • Length of ICU and Hospital Stay

    Measured in days (an expected average ICU stay=5 days and average Hospital stay=13 days and not more than 45 days)

  • Long-Term Anxiety and Depressive Symptoms (as measured by the Hospital Anxiety and Depression Scale (HADS)

    3 months after enrollment as measured by the Hospital Anxiety and Depression Scale (HADS)

  • Long-Term Posttraumatic Stress Symptoms (as measured by the PCL-5)

    3 months after enrollment as measured by the PCL-5

  • Health-Related Quality of Life (as measured by the EQ-5D-5L and SF-36)

    3 months after enrollment

Study Arms (2)

Anxiety Management (AM)

EXPERIMENTAL
Behavioral: Anxiety Management in the ICU

Usual Care (UC)

PLACEBO COMPARATOR
Other: Usual Care (UC)

Interventions

The AM intervention is based on a Cognitive-Behavioral Therapy (CBT) approach, empirically supported in other settings, though we do not know whether this approach will be effective for ICU patients. It will offer all participants core aspects of CBT including: (1) establish rapport/therapeutic alliance; (2) anxiety psychoeducation; (3) normalization of difficulties; (4) establishment of a sense of hope; (5) reflective listening; (6) supportive statements; (7) exposure to anxious thoughts/feelings; (8) directive statements; and (9) provision of coping strategies. It will consist of modules that include the aforementioned core aspects and "optional" modules based on each participant's anxiety experience and preference.

Anxiety Management (AM)

The UC group will receive usual care as per the Harborview Medical Center usual care standard. Because this is an effectiveness trial, treatment decisions for UC participants will be left to the discretion of the primary provider and/or primary medical team and may or may not include: (1) referral to rehab psychology C\&L service; (2) referral to psychiatry C\&L service; or (3) pharmacologic management.

Usual Care (UC)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years or older
  • Ability to read, write, and speak English
  • Alert (Best RASS ICU sedation score ≥-2)
  • Current CAM-ICU test negative
  • Expected ICU stay ≥48 hours
  • Anxiety Visual Analog Scale (VAS-A) score ≥30
  • Prescribed rehabilitation therapy at eligibility

You may not qualify if:

  • Inability to communicate (verbally, or via hand writing/gestures)
  • Greater than 90% probability of mortality in hospital
  • Anticipated discharge to hospice or transition to end-of-life care
  • Pre-existing cognitive impairment (e.g., dementia, pervasive developmental disorder)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Anxiety Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

April 10, 2015

First Posted

April 21, 2015

Study Start

April 1, 2015

Primary Completion

February 1, 2016

Last Updated

November 1, 2016

Record last verified: 2016-10